Avidity’s Phase I/II Success In Myotonic Dystrophy Obscured By Caveats
Dose-Dependent Response Unclear
Executive Summary
The US firm’s lead antibody oligonucleotide conjugate candidate has improved muscle strength and mobility in an early muscular dystrophy trial but some experts are disappointed by dose-specific data and a serious adverse event.